Merck Stock Declines Amid Patent Expiration Concerns

Merck & Co., Inc.'s (NYSE:MRK) stock traded down 1.9% during mid-day trading on Thursday, but despite this decline, analysts remain optimistic about the company's future prospects.

The company's stock has been subject to price fluctuations due to concerns over its blockbuster drug Keytruda's patent expiration and the need for revenue replacement.

However, analyst upgrades have provided a boost to investor confidence. Guggenheim raised its target from $146 to $170 and assigned a 'buy' rating, while Leerink Partners increased its target from $127 to $161 and upgraded its view to 'outperform.'

The company's recent presentation at the Wells Fargo healthcare conference may provide additional insight into its pipeline progress and strategy.